Ostrich Pharma USA Produces Antibodies to Block the Virus that Causes COVID-19

Ostrich Pharma USA has announced the successful development of ostrich antibodies to the SARS-CoV-2 virus, the expanding use of those antibodies in Japan, and plans for producing and deploying the antibodies in the U.S. Dr. Yasuhiro Tsukamoto, Dean of the Graduate School of Life and Environmental Sciences at Kyoto Prefectural University and Co-CEO of Ostrich Pharma USA, has injected a genetically engineered pseudovirus into ostriches, and antibodies were purified from their eggs. These antibodies demonstrate a strong ability to neutralize SARS-CoV-2 viruses. Dr. Tsukamoto said: “We have produced ostrich antibodies to many viruses, bacteria, and allergens, but we were pleased to see how quickly the ostriches developed immunity and placed the anti-SARS-CoV-2 antibodies in their eggs. We were even more pleased to see how capable the antibodies were in blocking the virus that causes COVID-19.